Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Investment Firm
|
| gptkbp:focus |
Biotechnology
Pharmaceuticals Technology |
| gptkbp:founded |
2015
|
| gptkbp:founder |
gptkb:Christian_Angermayer
|
| gptkbp:headquarters |
gptkb:Berlin,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Apeiron Investment Group
|
| gptkbp:investmentFocus |
Private Equity Firm
Long-term value creation Research-driven Innovative technologies Sector-focused Sustainable growth Impact investing Team-oriented Institutional Investor Early-stage companies Growth-stage companies Venture_Capital Venture_Capitalist |
| gptkbp:leadership |
gptkb:Dr._Andreas_Schmid
gptkb:Dr._Thomas_Schmid gptkb:Christian_Angermayer gptkb:Dr._Michael_Schmid |
| gptkbp:notableEvent |
gptkb:CureVac
Mediolanum Farmaceutici Apeiron_Biologics EQT_Life_Sciences Noxxon_Pharma |
| gptkbp:partnerships |
Research institutions
Various universities Healthcare_companies |
| gptkbp:portfolioCompany |
gptkb:CureVac_AG
Various startups Apeiron Biologics AG Mediolanum Farmaceutici S.p.A. EQT_Life_Sciences Noxxon_Pharma_AG |
| gptkbp:reputation |
Innovative investor
Active in venture capital Leader in biotech investments Strategic partner |
| gptkbp:website |
www.apeiron-invest.com
|